Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As subcutaneous monotherapy for adults with unresectable or metastatic hepatocellular carcinoma after prior sorafenib and IV nivolumab plus ipilimumab combination therapy.
LAMPGEN ANALYSIS
Why it matters
FDA converted the post-sorafenib use of the subcutaneous formulation from accelerated to traditional approval.
What research teams should watch
Verify the sorafenib and IV immunotherapy history before applying the converted label.
PRIMARY RECORDS